BioMarin Pharmaceutical Inc. Received approval from the FDA for Roctavian, along with the AAV5 DetectCDx, a diagnostic test that can assist healthcare providers in identifying patients who could benefit from using Roctavian to treat hemophilia A. This approval was granted on June 29, 2023.